Universidad Peruana Cayetano Heredia
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
JavaScript is disabled for your browser. Some features of this site may not work without it.
Mostrar el registro sencillo del ítem
| dc.contributor.author | Wheeler, D.C. | |
| dc.contributor.author | Stefansson, B.V. | |
| dc.contributor.author | Batiushin, M. | |
| dc.contributor.author | Bilchenko, O. | |
| dc.contributor.author | Cherney, D.Z.I. | |
| dc.contributor.author | Chertow, G.M. | |
| dc.contributor.author | Douthat, W. | |
| dc.contributor.author | Dwyer, J.P. | |
| dc.contributor.author | Escudero, E. | |
| dc.contributor.author | Pecoits-Filho, R. | |
| dc.contributor.author | Furuland, H. | |
| dc.contributor.author | Górriz, J.L. | |
| dc.contributor.author | Greene, T. | |
| dc.contributor.author | Haller, H. | |
| dc.contributor.author | Hou, F.F. | |
| dc.contributor.author | Kang, S.-W. | |
| dc.contributor.author | Isidto, R. | |
| dc.contributor.author | Khullar, D. | |
| dc.contributor.author | Mark, P.B. | |
| dc.contributor.author | McMurray, J.J.V. | |
| dc.contributor.author | Kashihara, N. | |
| dc.contributor.author | Nowicki, M. | |
| dc.contributor.author | Persson, F. | |
| dc.contributor.author | Correa-Rotter, R. | |
| dc.contributor.author | Rossing, P. | |
| dc.contributor.author | Toto, R.D. | |
| dc.contributor.author | Umanath, K. | |
| dc.contributor.author | Van Bui, P. | |
| dc.contributor.author | Wittmann, I. | |
| dc.contributor.author | Lindberg, M. | |
| dc.contributor.author | Sjöström, C.D. | |
| dc.contributor.author | Langkilde, A.M. | |
| dc.contributor.author | Heerspink, H.J.L. | |
| dc.date.accessioned | 2020-12-14T16:11:09Z | |
| dc.date.available | 2020-12-14T16:11:09Z | |
| dc.date.issued | 2020 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12866/8855 | |
| dc.description.abstract | BACKGROUND: The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD; NCT03036150) trial was designed to assess the effect of the sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin on kidney and cardiovascular events in participants with CKD with and without type 2 diabetes (T2D). This analysis reports the baseline characteristics of those recruited, comparing them with those enrolled in other trials. METHODS: In DAPA-CKD, 4304 participants with a urinary albumin:creatinine ratio (UACR) ≥200 mg/g and estimated glomerular filtration rate (eGFR) between 25 and 75 mL/min/1.73 m2 were randomized to dapagliflozin 10 mg once daily or placebo. Mean eGFR was 43.1 mL/min/1.73 m2 and median UACR was 949 mg/g (108 mg/mmol). RESULTS: Overall, 2906 participants (68%) had a diagnosis of T2D and of these, 396 had CKD ascribed to a cause other than diabetes. The most common causes of CKD after diabetes (n = 2510) were ischaemic/hypertensive nephropathy (n = 687) and chronic glomerulonephritis (n = 695), of which immunoglobulin A nephropathy (n = 270) was the most common. A total of 4174 participants (97%) were receiving an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, 1882 (43.7%) diuretics, 229 (5.3%) mineralocorticoid receptor antagonists and 122 (2.8%) glucagon-like peptide 1 receptor agonists. In contrast to the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), the DAPA-CKD trial enrolled participants with CKD due to diabetes and to causes other than diabetes. The mean eGFR of participants in the DAPA-CKD trial was 13.1 mL/min/1.73 m2 lower than in CREDENCE, similar to that in the Finerenone in Reducing Kidney Failure and Disease Progression in DKD (FIDELIO-DKD) trial and the Study Of diabetic Nephropathy with AtRasentan (SONAR). CONCLUSIONS: Participants with a wide range of underlying kidney diseases receiving renin-angiotensin system blocking therapy have been enrolled in the DAPA-CKD trial. The trial will examine the efficacy and safety of dapagliflozin in participants with CKD Stages 2-4 and increased albuminuria, with and without T2D. © The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA. | en_US |
| dc.language.iso | eng | |
| dc.publisher | Oxford University Press | |
| dc.relation.ispartofseries | Nephrology Dialysis Transplantation | |
| dc.rights | info:eu-repo/semantics/restrictedAccess | |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es | |
| dc.subject | chronic kidney disease | en_US |
| dc.subject | dapagliflozin | en_US |
| dc.subject | randomized controlled clinical trial | en_US |
| dc.subject | sodium–glucose co-transporter-2 inhibitor | en_US |
| dc.title | The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics | en_US |
| dc.type | info:eu-repo/semantics/article | |
| dc.identifier.doi | https://doi.org/10.1093/ndt/gfaa234 | |
| dc.subject.ocde | https://purl.org/pe-repo/ocde/ford#3.02.20 | |
| dc.subject.ocde | https://purl.org/pe-repo/ocde/ford#3.02.13 | |
| dc.relation.issn | 1460-2385 |
Ficheros en el ítem
| Ficheros | Tamaño | Formato | Ver |
|---|---|---|---|
|
No hay ficheros asociados a este ítem. |
|||
Este ítem aparece en la(s) siguiente(s) colección(ones)
-
Artículos en revistas indizadas [4988]
Recuperados de bases de datos bibliográficas
Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess
